NCT05184192View on ClinicalTrials.gov

Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 10, 2022

Primary Completion Date

August 29, 2023

Study Completion Date

August 29, 2023

Conditions

COVID-19Olfactory DisorderAnosmiaHyposmiaParosmia

Interventions

DRUG

Gabapentin gelatin capsules 300mg

Gabapentin is an anti-epileptic also used for nerve pain. This study will investigate the efficacy of gabapentin for olfactory nerve recovery and improvement in post-Covid-19 olfactory dysfunction.

DRUG

Placebo

lactose monohydrate NF

Trial Locations (1)

63110

Washington University, St Louis

All Listed Sponsors

lead

Washington University School of Medicine

OTHER

NCT05184192 - Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction | Biotech Hunter | Biotech Hunter